Rigaku and Emerald Bio Create Strategic Alliance
Rigaku (The Woodlands, Texas) has acquired the crystallization reagent and consumables business, including crystallization screening kits, from Emerald Bio (Bainbridge Island, Washington). The companies have agreed to work together to develop new products and solutions for the field of protein science.
Rigaku (The Woodlands, Texas) has acquired the crystallization reagent and consumables business, including crystallization screening kits, from Emerald Bio (Bainbridge Island, Washington). The companies have agreed to work together to develop new products and solutions for the field of protein science.
“The addition of these consumables and screening kits is another step in creating a single contact point for our instrumentation customers, improving the efficiency of their workflow,” said Catherine Klein, president of Rigaku Americas Corporation’s Life Sciences Division. “Further, having Emerald Bio as a development partner and customer will help ensure that we are at the forefront of new product needs in protein science.”
“Having Rigaku, the world leading protein crystallography instrumentation company, as a development partner is ideal for Emerald,” said Johan Pontin, CEO of Emerald Bio.
AI Boosts SERS for Next Generation Biomedical Breakthroughs
July 2nd 2025Researchers from Shanghai Jiao Tong University are harnessing artificial intelligence to elevate surface-enhanced Raman spectroscopy (SERS) for highly sensitive, multiplexed biomedical analysis, enabling faster diagnostics, imaging, and personalized treatments.
Machine Learning and Optical Spectroscopy Advance CNS Tumor Diagnostics
July 1st 2025A new review article highlights how researchers in Moscow are integrating machine learning with optical spectroscopy techniques to enhance real-time diagnosis and surgical precision in central nervous system tumor treatment.
